At the time of writing, Trevi Therapeutics Inc [TRVI] stock is trading at $6.55, up 2.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TRVI shares have gain 10.08% over the last week, with a monthly amount glided 0.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on July 01, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $25. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 28, 2025, and set its price target to $21. On March 10, 2025, upgrade upgraded it’s rating to Strong Buy and revised its price target to $29 on the stock. Needham reiterated its Buy rating and increased its price target to $25 on March 10, 2025. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $7.50 on December 12, 2024. In a note dated August 30, 2024, Raymond James initiated an Outperform rating and provided a target price of $9 on this stock.
For the past year, the stock price of Trevi Therapeutics Inc fluctuated between $2.36 and $7.48. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $6.55 at the most recent close of the market. An investor can expect a potential return of 22.14% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.58 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.33 points at the first support level, and at 6.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.68, and for the 2nd resistance point, it is at 6.81.
Ratios To Look Out For
It is important to note that Trevi Therapeutics Inc [NASDAQ:TRVI] has a current ratio of 15.38. Further, the Quick Ratio stands at 15.38, while the Cash Ratio is 2.82.
Transactions by insiders
Recent insider trading involved SCIASCIA THOMAS, Chief Scientific Officer, that happened on Mar 25 ’25 when 2631.0 shares were sold. President & CEO, GOOD JENNIFER L completed a deal on Mar 21 ’25 to sell 5263.0 shares. Meanwhile, Officer GOOD JENNIFER L bought 5263.0 shares on Mar 21 ’25.
